Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 92(10): 4611-5, 1995 May 09.
Article in English | MEDLINE | ID: mdl-7753850

ABSTRACT

Two endocytic receptors, the low density lipoprotein (LDL) receptor (LDLR) and the LDLR-related protein (LRP), are thought to act in concert in the hepatic uptake of partially metabolized dietary lipoproteins, the chylomicron remnants. We have evaluated the role of these two receptors in the hepatic metabolism of chylomicron remnants in normal mice and in LDLR-deficient [LDLR (-/-)] mice. The rate of chylomicron remnant removal by the liver was normal up to 30 min after intravenous injection of chylomicrons into LDLR (-/-) mice and was unaffected by receptor-associated protein (RAP), a potent inhibitor of ligand binding to LRP. In contrast, endocytosis of the remnants by the hepatocytes, measured by their accumulation in the endosomal fraction and by the rate of hydrolysis of component cholesteryl esters, was dramatically reduced in the absence of the LDLR. Coadministration of RAP prevented the continuing hepatic removal of chylomicron remnants in LDL (-/-) mice after 30 min, consistent with blockade of the slow endocytosis by a RAP-sensitive process. Taken together with previous studies, our results are consistent with a model in which the initial hepatic removal of chylomicron remnants is primarily mediated by mechanisms that do not include LDLR or LRP, possibly involving glycosaminoglycan-bound hepatic lipase and apolipoprotein E. After the remnants bind to these alternative sites on the hepatocyte surface, endocytosis is predominantly mediated by the LDLR and also by a slower and less efficient backup process that is RAP sensitive and therefore most likely involves LRP.


Subject(s)
Chylomicrons/metabolism , Endocytosis , Lipoproteins/blood , Liver/metabolism , Receptors, LDL/genetics , Receptors, LDL/metabolism , Analysis of Variance , Animals , Apolipoproteins/blood , Carrier Proteins/metabolism , Female , Glycoproteins/metabolism , Kinetics , LDL-Receptor Related Protein-Associated Protein , Low Density Lipoprotein Receptor-Related Protein-1 , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Immunologic/metabolism , Reference Values , Species Specificity
2.
J Lipid Res ; 32(6): 1039-48, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1658176

ABSTRACT

Circulating apolipoprotein J (apoJ) is a 70 kDa glycoprotein comprised of disulfide-linked alpha and beta subunits derived from a single precursor. Post-translational modifications that occur prior to apoJ secretion were assessed, with specific focus on carbohydrate type, the timing of proteolytic cleavage, and the importance of glycosylation on the cleavage and secretion processes. ApoJ was initially resolved as a single chain, intracellular precursor of 58 kDa which contained N-linked oligosaccharide but no O-linked oligosaccharide. The precursor was converted to an intracellular 70 kDa glycoprotein, which became the major intracellular form of apoJ prior to secretion. Maturation of the 58 kDa precursor involved conversion of high-mannose carbohydrate to complex-type carbohydrate containing sialic acid, as well as intracellular cleavage to yield alpha and beta subunits. This cleavage event occurred at a late stage of carbohydrate modification, most likely in the trans-Golgi or a post-Golgi compartment. The maturation and secretion of apoJ occurred rapidly, with a half-time of 30-35 min. Tunicamycin treatment of cells resulted in an unglycosylated doublet comprised of one single chain and one cleaved form of apoJ. The unglycosylated apoJ species were secreted rapidly with a half-time of 20 min. Both cleavage and secretion were independent of glycosylation.


Subject(s)
Apolipoproteins/metabolism , Lipoproteins, HDL/metabolism , Molecular Chaperones , Protein Precursors/metabolism , RNA Processing, Post-Transcriptional , Apolipoproteins/genetics , Carbohydrate Conformation , Carcinoma, Hepatocellular/metabolism , Cell Line , Clusterin , Glycoproteins/biosynthesis , Glycoproteins/metabolism , Glycosylation , Humans , Hydrolysis , Lipoproteins, HDL/genetics , Liver Neoplasms/metabolism , Protein Conformation , Protein Precursors/biosynthesis , Tumor Cells, Cultured , Tunicamycin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...